Medtronic (MDT) closed the latest trading day at $90.07, indicating a +0.92% change from the previous session's end. The stock outperformed the S&P 500, which registered a daily gain of 0.41%.

Dublin, Oct. 22, 2024 (GLOBE NEWSWIRE) -- The "Pain Management Devices Market, Industry Trends and Global Forecasts to 2035: ...

Medtronic is modestly undervalued based on DCF analysis, but slow revenue growth limits upside potential. Read why I ...

A former Medtronic consultant received an 18-month prison sentence this week for his role in a scheme linked to the $1.6 billion acquisition of an Israeli medical device company in 2018.

The three medtech firms unveiled new data this week during TCT 2024 in Washington, D.C. We look at what the results mean for ...

Medtronic MDT underwent analysis by 15 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to ...

Affera combines mapping technology with a catheter capable of performing radiofrequency and pulsed field ablation.

Medtronic plc has announced United States Food and Drug Administration (FDA) approval of the Affera Mapping and Ablation ...

In the most recent trading session, Medtronic (MDT) closed at $90.60, indicating a +0.01% shift from the previous trading day.

(Courtesy of Medtronic) At the time, pacemakers were “crude devices,” with wires coming out of the person’s body and “they ..

Less than a year after obtaining an FDA approval for its first foray into pulsed field ablation, Medtronic has done it again.